Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix: A third look

Claes Trope, John Erik Johnsson, Hans Grundsell, Willy Mattsson

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Twenty-four consecutive women with recurrence and/or metastasizing carcinoma of the cervix were treated with adriamycin and methotrexate. All patients had previously been treated with external irradiation and 2 intracavitary radium applications. The median recurrence-free interval was 22 months. All patients were evaluable. Five patients (21%) had partial remission for a median duration of 5 months (2 to 9 months), and 7 patients had static disease. When used in dosages that do not precipitate dangerous toxicity this therapy is not effective and in the authors' opinion should be abandoned.

Original languageEnglish (US)
Pages (from-to)488-492
Number of pages5
JournalObstetrics and gynecology
Volume55
Issue number4
StatePublished - Apr 1980

Fingerprint

Combination Drug Therapy
Methotrexate
Cervix Uteri
Doxorubicin
Carcinoma
Recurrence
Radium
Therapeutics

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix : A third look. / Trope, Claes; Johnsson, John Erik; Grundsell, Hans; Mattsson, Willy.

In: Obstetrics and gynecology, Vol. 55, No. 4, 04.1980, p. 488-492.

Research output: Contribution to journalArticle

Trope, Claes ; Johnsson, John Erik ; Grundsell, Hans ; Mattsson, Willy. / Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix : A third look. In: Obstetrics and gynecology. 1980 ; Vol. 55, No. 4. pp. 488-492.
@article{82437ba77eb44aa7abe5337cd6041dc9,
title = "Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix: A third look",
abstract = "Twenty-four consecutive women with recurrence and/or metastasizing carcinoma of the cervix were treated with adriamycin and methotrexate. All patients had previously been treated with external irradiation and 2 intracavitary radium applications. The median recurrence-free interval was 22 months. All patients were evaluable. Five patients (21{\%}) had partial remission for a median duration of 5 months (2 to 9 months), and 7 patients had static disease. When used in dosages that do not precipitate dangerous toxicity this therapy is not effective and in the authors' opinion should be abandoned.",
author = "Claes Trope and Johnsson, {John Erik} and Hans Grundsell and Willy Mattsson",
year = "1980",
month = "4",
language = "English (US)",
volume = "55",
pages = "488--492",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Adriamycin-methotrexate combination chemotherapy of advanced carcinoma of the cervix

T2 - A third look

AU - Trope, Claes

AU - Johnsson, John Erik

AU - Grundsell, Hans

AU - Mattsson, Willy

PY - 1980/4

Y1 - 1980/4

N2 - Twenty-four consecutive women with recurrence and/or metastasizing carcinoma of the cervix were treated with adriamycin and methotrexate. All patients had previously been treated with external irradiation and 2 intracavitary radium applications. The median recurrence-free interval was 22 months. All patients were evaluable. Five patients (21%) had partial remission for a median duration of 5 months (2 to 9 months), and 7 patients had static disease. When used in dosages that do not precipitate dangerous toxicity this therapy is not effective and in the authors' opinion should be abandoned.

AB - Twenty-four consecutive women with recurrence and/or metastasizing carcinoma of the cervix were treated with adriamycin and methotrexate. All patients had previously been treated with external irradiation and 2 intracavitary radium applications. The median recurrence-free interval was 22 months. All patients were evaluable. Five patients (21%) had partial remission for a median duration of 5 months (2 to 9 months), and 7 patients had static disease. When used in dosages that do not precipitate dangerous toxicity this therapy is not effective and in the authors' opinion should be abandoned.

UR - http://www.scopus.com/inward/record.url?scp=0018891301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018891301&partnerID=8YFLogxK

M3 - Article

C2 - 7366905

AN - SCOPUS:0018891301

VL - 55

SP - 488

EP - 492

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 4

ER -